ReviewVaccines2020
Covid-19-Associated Pulmonary Aspergillosis: The Other Side of the Coin.
Review in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Multidisciplinary collaborative treatment of a rare case of chronic hemoptysis: diagnostic and therapeutic insights from a 7-year clinical course.Frontiers in medicine · 2026Article
- Risk factors for identifying pulmonary aspergillosis in pediatric patients.Frontiers in cellular and infection microbiology · 2025Article
- Investigation of risk factors for invasive pulmonary aspergillosis among patients with COVID-19.Scientific reports · 2024Article
- Protective Effect of Indole-3-Aldehyde in Murine COVID-19-Associated Pulmonary Aspergillosis.Journal of fungi (Basel, Switzerland) · 2024Article
- The mRNA-LNP vaccines - the good, the bad and the ugly?Frontiers in immunology · 2024Review
- Knowledge Mapping of Aspergillus-Related Research in Respiratory Medicine: A Bibliometric Analysis Based on English-Language Articles Spanning 1975 to 2022.Canadian respiratory journal · 2024Article
- Thymosin α1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical Application.Molecules (Basel, Switzerland) · 2023Review
- Indications that the Antimycotic Drug Amphotericin B Enhances the Impact of Platelets on Aspergillus.Antimicrobial agents and chemotherapy · 2022Article
- Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion.PLoS pathogens · 2022Article
- Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion.bioRxiv : the preprint server for biology · 2022Article
- Performance of Two Commercial Assays for the Detection of SerumJournal of fungi (Basel, Switzerland) · 2022Article
- COVID-19 and Fungal Diseases.Antibiotics (Basel, Switzerland) · 2022Review
- SARS-CoV-2 Associated Immune Dysregulation and COVID-Associated Pulmonary Aspergilliosis (CAPA): A Cautionary Tale.International journal of molecular sciences · 2022Review
- Overview of COVID-19-Associated Invasive Fungal Infection.Current fungal infection reports · 2022Review
- Coronavirus Disease 2019-Associated Invasive Fungal Infection.Open forum infectious diseases · 2021Article
- Overview on the Prevalence of Fungal Infections, Immune Response, and Microbiome Role in COVID-19 Patients.Journal of fungi (Basel, Switzerland) · 2021Review
- Epidemiology and Incidence of COVID-19-Associated Pulmonary Aspergillosis (CAPA) in a Greek Tertiary Care Academic Reference Hospital.Infectious diseases and therapy · 2021Article
- COVID-19-associated pulmonary aspergillosis: a prospective single-center dual case series.Mycoses · 2021Article
- COVID-19-Associated Pulmonary Aspergillosis, March-August 2020.Emerging infectious diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 3 countries.
Funding
Abstract
The immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a critical factor in the clinical presentation of COVID-19, which may range from asymptomatic to a fatal, multi-organ disease. A dysregulated immune response not only compromises the ability of the host to resolve the viral infection, but may also predispose the individual to secondary bacterial and fungal infections, a risk to which the current therapeutic immunomodulatory approaches significantly contribute. Among the secondary infections that may occur in COVID-19 patients, coronavirus-associated pulmonary aspergillosis (CAPA) is emerging as a potential cause of morbidity and mortality, although many aspects of the disease still remain unresolved. With this opinion, we present the current view of CAPA and discuss how the same mechanisms that underlie the dysregulated immune response in COVID-19 increase susceptibility to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.